Carboprost — Membership Pricing

Other medications in Women's Health

• Clomiphene Citrate
• Danazol
• Desogestrel-Ethinyl Estradiol
• Dienogest
• Dinoprostone
• Drospirenone-Ethinyl Estradiol
• Elagolix
• Emergency Contraception

What Carboprost is approved for (FDA label)

Carboprost tromethamine injection sterile solution is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: 1. Failure of expulsion of the fetus during the course of treatment by another method; 2. Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; 3. Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; 4. Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion.

Source: Read the full FDA label on DailyMed. Label effective date: June 5, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Carboprost (FDA label)

WARNING Carboprost tromethamine injection sterile solution (carboprost tromethamine), like other potent oxytocic agents, should be used only with strict adherence to recommended dosages. Carboprost tromethamine injection should be used by medically trained personnel in a hospital which can provide immediate intensive care and acute surgical facilities.

Source: FDA prescribing information (DailyMed). Set ID: d79f4342-2d37-4a47-958e-ab800d4f3918. SPL document ID: a555e571-aeb9-4b61-9bb3-68c85db43fc9. Label effective date: June 5, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Carboprost (FDA label)

The adverse effects of carboprost tromethamine injection sterile solution are generally transient and reversible when therapy ends. The most frequent adverse reactions observed are related to its contractile effect on smooth muscle. In patients studied, approximately two-thirds experienced vomiting and diarrhea, approximately one-third had nausea, one-eighth had a temperature increase greater than 2° F, and one-fourteenth experienced flushing. The pretreatment or concurrent administration of antiemetic and antidiarrheal drugs decreases considerably the very high incidence of gastrointestinal effects common with all prostaglandins used for abortion. Their use should be considered an integral part of the management of patients undergoing abortion with carboprost tromethamine injection. Of those patients experiencing a temperature elevation, approximately one-sixteenth had a clinical diagnosis of endometritis.

Source: FDA prescribing information (DailyMed). Set ID: d79f4342-2d37-4a47-958e-ab800d4f3918. SPL document ID: a555e571-aeb9-4b61-9bb3-68c85db43fc9. Label effective date: June 5, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Carboprost (FDA label)

1. Hypersensitivity (including anaphylaxis and angioedema) to carboprost tromethamine injection sterile solution [ see ADVERSE REACTIONS, Post-marketing Experience ] 2. Acute pelvic inflammatory disease 3. Patients with active cardiac, pulmonary, renal or hepatic disease

Source: FDA prescribing information (DailyMed). Set ID: d79f4342-2d37-4a47-958e-ab800d4f3918. SPL document ID: a555e571-aeb9-4b61-9bb3-68c85db43fc9. Label effective date: June 5, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.